There is an ever-growing demand for transplantable organs to replace acute and chronically damaged tissues. This demand cannot be met by the currently available donor organs. Efforts to provide an alternative source have led to the development of organ engineering, a discipline that combines cell biology, tissue engineering, and cell/organ transplantation. Over the last several years, engineered organs have been implanted into rodent recipients and have shown modest function. In this article, we summarize the most recent advances in this field and provide a perspective on the challenges of translating this promising new technology into a proven regenerative therapy.Conflict of interest: Thomas W. Gilbert served on the scientific advisory board of ACell Inc. during the writing of this manuscript. Since acceptance of the manuscript, he became the Vice President of Research and Development at ACell Inc., which commercializes ECM from porcine urinary bladder for clinical use in tissue repair. Jason A. Wertheim reports expenses paid by Cellular Dynamics International for research-related travel that is unrelated to the preparation of this manuscript.
Citation for this article: